Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Empagliflozin + Linagliptin vs Glyxambi in Healthy Adults
NCT07039890Phase 1Completed
- Sponsor
- Humanis
- Start
- Mar 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin + linagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Humanis. Primary endpoints: Peak Plasma Concentration at 72 hours, Area Under the Curve from time zero to time of last measurable concentration at 72 hours and 1 more. Started Mar 2025; status: completed.
02
Drugs
empagliflozin + linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07039890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07039890.